CA9 and head and neck cancer: The feasibility of F-flortanidazole (18F-HX4) head and neck cancer was tested comparatively with F-MISO in twelve patients, showing several qualities: possibility for imaging within a shorter time period after injection (<2 h), high sensitivity and specificity and good correlation with CA-IX expression [20].